Drug pricing reform continues



​Portfolio Manager Ethan Lovell discusses a new proposal to overhaul drug pricing in the US in Medicare Part B and what it could mean for drug manufacturers.

In another step toward reforming drug pricing, the US Department of Health and Human Services (HHS) recently introduced a proposal to change how drug prices are set in Medicare Part B. According to the proposal, prices would be tied to a so-called International Pricing Index (IPI) based on costs in other countries such as Canada, Japan and the UK. According to an analysis by HHS, the prices of physician-administered drugs in Medicare Part B were 1.8x higher than prices in 16 other developed economies. By moving to the IPI model, HHS estimates total spending in the US for these drugs would fall by roughly 30%.

The potential impact to drug makers

At first blush, HHS's proposal may seem negative for drug makers as it would limit companies’ pricing power. However, as is often the case in healthcare reform, the details must be considered.

According to HHS and the Centers for Medicare and Medicaid Services, annual US drug spending in Medicare Part B was $28 billion in 2016, a third of the total outlay in Part D (Medicare’s standalone outpatient drug benefit). Medicare Part B primarily covers drugs administered by a doctor or affiliated health care professional. The new proposal would exclude patients in Medicare Advantage plans (who account for about a third of Part B participants). Even then, among qualifying patients, the proposal would apply to just 50% of people (a limitation needed in order to avoid Congress from weighing in) and would roll out over a five-year period, starting in 2020. In addition, HHS is in the process of soliciting comments on the proposal, which won’t be finalised until next year.

The net effect

We think the bite from the IPI model is likely to be minimal when you consider that Medicare Part B accounts for only a small percentage of the $1 trillion global pharmaceutical market. Furthermore, initial proposals tend to be more draconian than what eventually gets implemented as industry participants argue their case. For many companies, we think the IPI model would be, at its worst, a minor headwind to earnings.

What’s next?

In the near term, some stocks could be pressured, particularly those of drug manufacturers that have a large presence in Part B. However, we believe many of these firms have other long-term growth drivers in their business models. Should the IPI proposal create market volatility and weigh on valuations, these drivers could become all the more attractive.

To be clear, we think Medicare Part B is due for change. Under the current system, healthcare providers purchase medicines and are reimbursed based on an average sales price for the drug, plus an add-on of 6%. Because the add-on is a percentage, doctors have a financial incentive to prescribe higher-cost medicines. The proposed reform would remove doctors from the purchase of drugs – giving the responsibility to private vendors – and pay doctors a flat fee for handling and storing medicines.

These reforms seem like a step in the right direction for Medicare Part B. Can they be applied to larger areas of the US pharmaceutical market, such as Part D? We don’t think so. Already in Part D, plan administrators such as United Healthcare work with drug makers to establish prices in exchange for placement on a plan formulary. Introducing an IPI model, where the government establishes price, would require a legislative overhaul and could face litigation. Even though the Republicans maintained their majority position in the Senate after the midterm elections, the party will still need a broad coalition of support to effect change.

Meanwhile, the industry may act preemptively to satisfy President Trump’s dogged pursuit of lowering drug prices in the US. Already, major biopharmaceutical companies such as Amgen and Gilead have lowered the list price of brand drugs for cash-paying customers. We could see more firms follow suit – and with potentially little detriment to the bottom line. After all, the net price realised by drug makers tends to be much lower than the list price after accounting for rebates paid to companies that manage prescription benefit plans for insurers. However, these rebates do not show up at the point of sale as financial concessions for consumers to enjoy. By lowering the list price and effectively eliminating rebates, drug manufacturers could improve patient affordability and consequently drive up sales volumes. In the end, that’s better for patients and better for the drug industry.



Medicare (part B and part D): the national health insurance programme administered in the US for people over the age of 65 and younger people with a disability status. Medicare B plan is a subsection of the Medicare programme, where costs for medically necessary and preventative services are covered. In the Medicare part D plan, the cost of prescription medication for beneficiaries is subsidised by the US Federal Government.


These are the views of the author at the time of publication and may differ from the views of other individuals/teams at Janus Henderson Investors. Any securities, funds, sectors and indices mentioned within this article do not constitute or form part of any offer or solicitation to buy or sell them.

Past performance is not a guide to future performance. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested.

The information in this article does not qualify as an investment recommendation.

For promotional purposes.

Important information

Please read the following important information regarding funds related to this article.

Janus Henderson Global Life Sciences Fund

For institutional/ sophisticated investors / accredited investors qualified distributors use only.

All content in this document is for information or general use only and is not specific to any individual client requirements. The information contained in this document is referential and may not be construed as an offer, invitation or recommendation or investment advice, nor should be taken as a basis to take (or stop taking) any decision.

Janus Henderson Capital Funds Plc is a UCITS established under Irish law, with segregated liability between funds. Investors are warned that they should only make their investments based on the most recent Prospectus which contains information about fees, expenses and risks, which is available from all distributors and paying agents, it should be read carefully. An investment in the fund may not be suitable for all investors and is not available to all investors in all jurisdictions; it is not available to US persons.  Past performance is not indicative of future results. The rate of return may vary and the principal value of an investment will fluctuate due to market and foreign exchange movements.  Shares, if redeemed, may be worth more or less than their original cost.

Janus Henderson Group plc and its subsidiaries are not responsible for any unlawful distribution of this document to any third parties, in whole or in part, or for information reconstructed from this document and do not guarantee that the information supplied is accurate, complete, or timely, or make any warranties with regards to the results obtained from its use. As with all investments, there are inherent risks that each individual should address.

The distribution of this document or the information contained in it may be restricted by law and may not be used in any jurisdiction or any circumstances in which its use would be unlawful.

Issued in Europe by Janus Capital International Limited (“JCIL”), authorised and regulated by the U.K. Financial Conduct Authority. Janus Capital International Limited (“JCIL”) is an entity registered and operating under the laws of the United Kingdom and Janus Capital Funds plc. is registered under the legislation of Ireland.

The extract prospectus (edition for Switzerland), the articles of incorporation, the extract annual and semi-annual report, in German, can be obtained free of charge from the representative in Switzerland: First Independent Fund Services Ltd (“FIFS”), Klausstrasse 33, CH-8008 Zurich, Switzerland, tel: +41 44 206 16 40, fax: +41 44 206 16 41, web: http://www.fifs.ch. The Swiss paying agent is: Banque Cantonale de Genève, 17, quai de l’Ile, CH-1204 Geneva. The last share prices can be found on www.fundinfo.com. For Qualified investors, institutional, wholesale client use only. Outside of Switzerland, this document is for professional use only. Not for onward distribution.

This material is strictly private and confidential and may not be reproduced or used for any purpose other than evaluation of a potential investment in Janus Capital International Limited’s products or the procurement of its services by the recipient of this presentation or provided to any person or entity other than the recipient of this presentation.

We may record telephone calls for our mutual protection, to improve customer service and for regulatory record keeping purposes.

Janus Capital Management LLC serves as investment adviser. Janus, Intech and Perkins are registered trademarks of Janus International Holding LLC. © Janus International Holding LLC. For more information or to locate your country’s Janus representative contact information, please visit www.janushenderson.com.

Specific risks

  • This fund is designed to be used only as one component of several in a diversified investment portfolio. Investors should consider carefully the proportion of their portfolio invested into this fund.
  • If a Fund has a high exposure to a particular country or geographical region it carries a higher level of risk than a Fund which is more broadly diversified.
  • The Fund may use derivatives with the aim of reducing risk or managing the portfolio more efficiently. However this introduces other risks, in particular, that a derivative counterparty may not meet its contractual obligations.
  • Shares can lose value rapidly, and typically involve higher risks than bonds or money market instruments. The value of your investment may fall as a result.
  • If the Fund holds assets in currencies other than the base currency of the Fund or you invest in a share class of a different currency to the Fund (unless 'hedged'), the value of your investment may be impacted by changes in exchange rates.
  • The Fund is focused towards particular industries or investment themes and may be heavily impacted by factors such as changes in government regulation, increased price competition, technological advancements and other adverse events.
  • Shares of small and mid-size companies can be more volatile than shares of larger companies, and at times it may be difficult to value or to sell shares at desired times and prices, increasing the risk of losses.

Risk rating


Important message